Form 8-K · Current Report · Filed 2024-01-09
Cardinal Health Announces Progress on Business and Portfolio Review and Fiscal 2024 Outlook Update
Cardinal Health, Inc. announced progress on its ongoing business and portfolio review, including an updated enterprise operating and segment reporting structure effective January 1, 2024, and an update to its fiscal year 2024 non-GAAP diluted earnings per share (EPS) outlook. The company updated its fiscal 2024 non-GAAP diluted EPS guidance to the high end of its $6.75 to $7.00 range. The company also provided an update to its previous expectations for Medical segment profit for the quarter ended December 31, 2023. Cardinal Health will host a conference call to discuss these announcements. A copy of the news release is included as Exhibit 99.1 to this report.
- Filer
- Cardinal Health Inc. CAH · NYSE
- Filed
- Accession
- 0000721371-24-000005
- CIK
- 0000721371
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Regulation FD Disclosure
Financial Statements and Exhibits
Market reaction
Close before filing
$105.17
Next session
-0.9%
Since filing
+118.7%
Latest close
$230.03
What happened, not what will happen — closing prices around the filing date.
Exhibits (1)
About Cardinal Health Inc.
Cardinal Health Inc. is a major global healthcare services and products company, distinguished for providing end-to-end medical solutions. Specializing in healthcare distribution and supply chain management, Cardinal Health serves a comprehensive array of clients including hospitals, pharmacies, and healthcare providers. Notably, the company distributes pharmaceuticals, medical products, and laboratory supplies, ensuring efficient delivery to improve healthcare outcomes. Based in Dublin, Ohio, Cardinal Health plays a pivotal role in enhancing healthcare operational efficiency, offering extensive services like inventory management, logistics optimization, and integrated healthcare solutions that empower providers to focus on patient care. As one of the largest pharmaceutical distributors in the United States, it holds substantial influence in the healthcare sector, pivotal in ensuring the availability of drugs and medical supplies across various platforms, contributing significantly to the healthcare infrastructure worldwide.
Never miss another CAH filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.